Balaxi Pharmaceuticals Ltd

AI

Balaxi Pharmaceuticals Ltd

₹ 37.3 17.85%
19 Nov - close price
About

Balaxi Pharmaceuticals Ltd is an IPR-based pharmaceutical Company engaged in producing, stocking, selling, and supplying branded and generic medicines. [1]

Key Points

Product Portfolio:[1]
The Co's portfolio includes a balanced mix of generic and branded generic medicines. The strongest product categories are Antibiotics (84 products), Analgesics (65 products), Medical Devices (32 products) and Vitamins **(26 products) **

  • Market Cap ₹ 206 Cr.
  • Current Price ₹ 37.3
  • High / Low ₹ 41.0 / 15.2
  • Stock P/E 61.1
  • Book Value ₹ 46.0
  • Dividend Yield 0.00 %
  • ROCE 3.47 %
  • ROE 0.59 %
  • Face Value ₹ 2.00

Pros

  • Stock is trading at 0.81 times its book value

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend
  • The company has delivered a poor sales growth of 3.15% over past five years.
  • Company has a low return on equity of -3.58% over last 3 years.
  • Company has high debtors of 184 days.
  • Promoter holding has decreased over last 3 years: -5.23%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
54.72 60.79 59.83 65.62 77.38 73.29 76.27 70.74 56.18 72.54 70.71 80.68 81.37
43.96 47.14 46.36 55.53 66.79 69.30 63.72 66.58 55.02 69.45 70.59 76.02 76.24
Operating Profit 10.76 13.65 13.47 10.09 10.59 3.99 12.55 4.16 1.16 3.09 0.12 4.66 5.13
OPM % 19.66% 22.45% 22.51% 15.38% 13.69% 5.44% 16.45% 5.88% 2.06% 4.26% 0.17% 5.78% 6.30%
5.93 1.51 -0.70 -1.85 -4.11 3.94 -1.69 -1.78 1.59 0.10 2.92 -0.99 -0.83
Interest 0.37 0.41 0.61 0.37 0.45 1.38 0.74 1.01 0.89 1.02 0.99 0.73 0.86
Depreciation 0.66 0.48 0.67 0.49 0.46 0.48 0.46 0.46 0.48 0.56 0.65 0.85 1.42
Profit before tax 15.66 14.27 11.49 7.38 5.57 6.07 9.66 0.91 1.38 1.61 1.40 2.09 2.02
Tax % 7.92% 4.77% 4.87% 12.06% 17.41% 11.70% 10.56% 67.03% 84.06% 80.75% 56.43% 38.28% 43.07%
14.43 13.59 10.93 6.48 4.59 5.36 8.64 0.29 0.21 0.31 0.61 1.30 1.15
EPS in Rs 2.82 2.65 2.01 1.17 0.83 0.97 1.57 0.05 0.04 0.06 0.11 0.24 0.21
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
0 0 0 0 14 46 231 279 336 241 293 270 305
0 0 0 1 12 37 189 229 279 197 254 261 292
Operating Profit 0 -0 -0 -1 2 8 43 51 57 45 38 10 13
OPM % 33% -120% 11% 18% 18% 18% 17% 18% 13% 3.5% 4.3%
0 0 0 0 1 1 2 5 3 -38 -4 3 1
Interest 0 0 0 0 0 0 0 1 1 3 4 5 4
Depreciation 0 0 0 0 0 0 0 1 2 2 2 2 3
Profit before tax 0 -0 -0 -1 2 9 44 55 57 2 29 5 7
Tax % 27% -36% 0% 0% 19% 31% 14% 13% 19% 219% 13% 73%
0 -0 -0 -1 2 6 38 48 46 -2 25 1 3
EPS in Rs 0.07 -0.05 -0.11 -0.51 1.30 1.22 7.63 9.53 9.03 -0.44 4.54 0.26 0.62
Dividend Payout % 91% 0% 0% 0% 0% 0% 0% 1% 0% 0% 0% 0%

(S): Standalone figures, shown where consolidated figures are not available.

Compounded Sales Growth
10 Years: %
5 Years: 3%
3 Years: -7%
TTM: 10%
Compounded Profit Growth
10 Years: %
5 Years: -48%
3 Years: -69%
TTM: -77%
Stock Price CAGR
10 Years: 27%
5 Years: -20%
3 Years: -23%
1 Year: 4%
Return on Equity
10 Years: %
5 Years: 8%
3 Years: -4%
Last Year: 1%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Equity Capital 3 3 3 3 3 10 10 10 10 11 11 11 11
Reserves 0 0 -1 -1 0 18 55 103 173 190 221 238 243
0 0 0 0 0 0 4 4 13 19 53 58 52
0 0 0 0 3 8 31 60 43 38 25 30 36
Total Liabilities 4 4 2 2 6 36 100 176 240 258 310 337 341
0 0 0 0 0 0 2 29 41 41 41 82 82
CWIP 0 0 0 0 0 0 0 1 3 2 22 0 0
Investments 3 3 0 0 0 0 3 0 0 0 0 0 0
0 0 2 2 6 36 94 147 195 215 247 255 259
Total Assets 4 4 2 2 6 36 100 176 240 258 310 337 341

(S): Standalone figures, shown where consolidated figures are not available.

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
0 -0 -0 -1 -2 -14 0 34 6 5 -35 -4
-3 0 3 -0 -0 -0 -6 -28 -11 -1 -22 -21
2 -0 -0 0 0 18 4 -0 26 30 34 0
Net Cash Flow -1 -0 2 -1 -2 4 -2 6 21 34 -23 -25
Free Cash Flow 0 -0 -0 -1 -2 -14 -3 7 -9 4 -57 -25
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 700% 50% 100% 88% -97% -161% 6% 78% 32% 26% -83% 2%

(S): Standalone figures, shown where consolidated figures are not available.

Ratios

Consolidated / View Standalone

Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 30 0 147 238 121 36 57 84 138 184
Inventory Days 9 29 184 189 233 173 202
Days Payable 64 53 92 62 82 36 51
Cash Conversion Cycle 30 0 147 183 97 129 184 235 275 335
Working Capital Days -669 -1,387 82 181 91 92 122 142 186 236
ROCE % 8% -2% -5% -40% 57% 93% 60% 37% 21% 13% 3%

(S): Standalone figures, shown where consolidated figures are not available.

Insights

In beta
Mar 2021 Mar 2026
Branded Generics Share of Pharma Product Mix
%

Log in to view insights

Please log in to see hidden values.

Login
Pharma Revenue Share - Africa (Angola + CAR)
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

1 Recently
Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
71.22% 66.86% 65.99% 65.99% 65.99% 65.99% 65.99% 65.99% 65.99% 65.99% 65.99% 65.99%
18.57% 17.21% 16.88% 16.48% 16.48% 16.02% 8.87% 3.50% 1.74% 0.00% 0.00% 0.00%
0.03% 0.02% 0.02% 0.02% 0.02% 0.02% 0.02% 0.02% 0.02% 2.56% 2.56% 2.56%
10.18% 15.91% 17.11% 17.50% 17.50% 17.96% 25.12% 30.49% 32.24% 31.45% 31.45% 31.45%
No. of Shareholders 5,0455,2066,5867,8638,5299,99413,73714,62015,08515,17614,68214,474

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Annual reports

Concalls